Our study indicates that PI3K inhibitor in inhibiting Akt and subsequent destabilization of E6AP even under the treatment of EGF may be potential for clinical treatment of cervical cancer patients infected with HPV. This evidence concerns the gene UBE3A and cervical cancer.